| Name | Title | Contact Details |
|---|
Dionex Corporation (Dionex) designs, manufactures, markets, and services analytical instrumentation, related accessories, and chemicals. Its products are used to analyze chemical substances in the environment and in a range of industrial and scientific
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company`s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO.
Biomet, Inc. is one of the world's leading medical device manufacturers located in the Warsaw, Indiana business cluster. The company specializes in reconstructive products for hips, knees and shoulders, fixation devices, orthopedic support devices, dental implants, spinal implants and operating room supplies. Biomet was established in 1977 and delivered its first hip replacement in 1978. In a September 2007 club deal the company was acquired by a consortium of private equity firms and ceased trading on NASDAQ.
Sorenson BioScience is a manufacturer of disposable plastic liquid handling products. Located in Salt Lake City, Utah, it was founded in 1981 as Mµlti Technology, Inc. The company rapidly became an innovator in the manufacture of liquid handling products
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.